JP2020524687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524687A5 JP2020524687A5 JP2019570547A JP2019570547A JP2020524687A5 JP 2020524687 A5 JP2020524687 A5 JP 2020524687A5 JP 2019570547 A JP2019570547 A JP 2019570547A JP 2019570547 A JP2019570547 A JP 2019570547A JP 2020524687 A5 JP2020524687 A5 JP 2020524687A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- pyridin
- dihydro
- dimethyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 58
- 150000001204 N-oxides Chemical class 0.000 claims 50
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 37
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 29
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 206010002022 amyloidosis Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- QFQAXYYKZBIRPP-HOTGVXAUSA-N 5,6,7-trimethyl-2-[2-[(1S,2R)-2-pyridin-3-ylcyclopropyl]acetyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-one Chemical compound CN1C(C2=C(C(=C1C)C)CN(C2)C(C[C@H]1[C@@H](C1)C=1C=NC=CC=1)=O)=O QFQAXYYKZBIRPP-HOTGVXAUSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- SDZQJMCXLDSQML-UHFFFAOYSA-N 1-[6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]-3-(1H-pyrazol-4-yl)propan-1-one Chemical compound CC1=C(C2=C(C(=N1)NC)CN(C2)C(CCC=1C=NNC=1)=O)C SDZQJMCXLDSQML-UHFFFAOYSA-N 0.000 claims 1
- YHVZLWRQGISNQE-UHFFFAOYSA-N 1-[6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]-3-(4-methoxyphenyl)propan-1-one Chemical compound C1=C(C=CC(=C1)CCC(=O)N1CC2=C(C(=NC(=C2C)C)NC)C1)OC YHVZLWRQGISNQE-UHFFFAOYSA-N 0.000 claims 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 claims 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 1
- YPHCYHOTYHNIMX-UHFFFAOYSA-N 4-[3-[2-[6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]-2-oxoethyl]azetidin-1-yl]pyridine-2-carbonitrile Chemical compound CC1=C(C2=C(C(=N1)NC)CN(C2)C(CC1CN(C1)C1=CC(=NC=C1)C#N)=O)C YPHCYHOTYHNIMX-UHFFFAOYSA-N 0.000 claims 1
- NACFKBRRTJAIRY-UHFFFAOYSA-N 4-[3-[6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]-3-oxopropyl]benzonitrile Chemical compound C1=C(C=CC(=C1)CCC(=O)N1CC2=C(C(=NC(=C2C)C)NC)C1)C#N NACFKBRRTJAIRY-UHFFFAOYSA-N 0.000 claims 1
- YRZUDHYYIUIDIZ-UHFFFAOYSA-N 5,6,7-trimethyl-2-[2-(1-pyridin-3-ylazetidin-3-yl)acetyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-one Chemical compound N1(C2=CN=CC=C2)CC(CC(=O)N2CC3=C(C(=O)N(C(=C3C)C)C)C2)C1 YRZUDHYYIUIDIZ-UHFFFAOYSA-N 0.000 claims 1
- MASQMSKSYJLVPR-UHFFFAOYSA-N 5,6,7-trimethyl-2-[2-[1-[2-(trifluoromethyl)pyridin-4-yl]azetidin-3-yl]acetyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-one Chemical compound N1(C2=CC(C(F)(F)F)=NC=C2)CC(CC(=O)N2CC3=C(C(=O)N(C(=C3C)C)C)C2)C1 MASQMSKSYJLVPR-UHFFFAOYSA-N 0.000 claims 1
- LYYCRODRVBDGRZ-UHFFFAOYSA-N 6,7-dimethyl-2-[2-(1-pyridin-3-ylazetidin-3-yl)acetyl]-3,5-dihydro-1H-pyrrolo[3,4-c]pyridin-4-one Chemical compound N1(C2=CN=CC=C2)CC(CC(=O)N2CC3=C(C(=O)NC(C)=C3C)C2)C1 LYYCRODRVBDGRZ-UHFFFAOYSA-N 0.000 claims 1
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- MXKFZWRULHJPIV-LLVKDONJSA-N [6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]-[(3R)-oxolan-3-yl]methanone Chemical compound O1CC[C@H](C1)C(=O)N1CC2=C(C(=NC(=C2C)C)NC)C1 MXKFZWRULHJPIV-LLVKDONJSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- FQCIVZDKIPZMHS-UHFFFAOYSA-N cyclopropyl-[6,7-dimethyl-4-(methylamino)-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]methanone Chemical compound C1(C(=O)N2CC3=C(C(=NC(=C3C2)NC)C)C)CC1 FQCIVZDKIPZMHS-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523306P | 2017-06-22 | 2017-06-22 | |
| US62/523,306 | 2017-06-22 | ||
| PCT/IB2018/054390 WO2018234953A1 (en) | 2017-06-22 | 2018-06-14 | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524687A JP2020524687A (ja) | 2020-08-20 |
| JP2020524687A5 true JP2020524687A5 (https=) | 2021-07-26 |
| JP7263266B2 JP7263266B2 (ja) | 2023-04-24 |
Family
ID=62981279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570547A Active JP7263266B2 (ja) | 2017-06-22 | 2018-06-14 | ジヒドロ－ピロロ－ピリジン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11198692B2 (https=) |
| EP (1) | EP3642202B1 (https=) |
| JP (1) | JP7263266B2 (https=) |
| KR (1) | KR20200013783A (https=) |
| CN (1) | CN110944998B (https=) |
| AU (1) | AU2018287787A1 (https=) |
| BR (1) | BR112019026955A2 (https=) |
| CA (1) | CA3066986A1 (https=) |
| DK (1) | DK3642202T3 (https=) |
| ES (1) | ES2937236T3 (https=) |
| FI (1) | FI3642202T3 (https=) |
| HU (1) | HUE060914T2 (https=) |
| IL (1) | IL271290B2 (https=) |
| MX (1) | MX2019015371A (https=) |
| PL (1) | PL3642202T3 (https=) |
| PT (1) | PT3642202T (https=) |
| SG (1) | SG11201913014YA (https=) |
| TW (1) | TWI680128B (https=) |
| WO (1) | WO2018234953A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4061813B1 (en) * | 2019-11-22 | 2025-06-04 | F. Hoffmann-La Roche AG | Pyrrolidine derivatives |
| CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| WO2024088408A1 (zh) * | 2022-10-28 | 2024-05-02 | 纽欧申医药(上海)有限公司 | 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用 |
| KR20250133677A (ko) * | 2022-12-16 | 2025-09-08 | 카루나 세러퓨틱스 인코포레이티드 | 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도 |
| EP4634181A1 (en) | 2022-12-16 | 2025-10-22 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| EP4634183A1 (en) * | 2022-12-16 | 2025-10-22 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| WO2024130064A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| WO2024130068A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions |
| AU2024311336A1 (en) * | 2023-06-20 | 2026-01-22 | Haisco Pharmaceutical Group Co., Ltd. | Muscarinic m4 receptor agonist and use thereof |
| WO2025055970A1 (zh) * | 2023-09-15 | 2025-03-20 | 江苏恩华药业股份有限公司 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025083630A1 (en) | 2023-10-19 | 2025-04-24 | Suven Life Sciences Limited | Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025099660A1 (en) | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| TW202540094A (zh) * | 2023-11-17 | 2025-10-16 | 大陸商上海翰森生物醫藥科技有限公司 | 雜環羰基類衍生物調節劑、其製備方法與應用 |
| AR134570A1 (es) * | 2023-12-07 | 2026-01-28 | Acadia Pharm Inc | Moduladores alostéricos positivos de m4 |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
| WO2025134078A1 (en) | 2023-12-22 | 2025-06-26 | Suven Life Sciences Limited | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2026037961A1 (en) | 2024-08-15 | 2026-02-19 | Neurosterix Pharma Sàrl | 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor |
| WO2026037949A1 (en) | 2024-08-15 | 2026-02-19 | Neurosterix Pharma Sàrl | 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor |
| WO2026047494A1 (en) | 2024-08-26 | 2026-03-05 | Suven Life Sciences Limited | 2-AMINO-PYRIMIDINE DERIVATIVES AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3123612A (en) * | 1964-03-03 | Z-acylated z | ||
| US2767191A (en) * | 1953-12-31 | 1956-10-16 | American Cyanamid Co | Dihydropyrrolo-pyridines |
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP2000109481A (ja) * | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| ES2349416T3 (es) | 2004-10-25 | 2011-01-03 | Eli Lilly And Company | Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4. |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| DE602006010665D1 (en) * | 2005-02-07 | 2010-01-07 | Hoffmann La Roche | Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1 |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| CA2608018C (en) | 2005-05-12 | 2010-07-13 | Pfizer Inc. | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| US20100273772A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
| US8664234B2 (en) | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
| AU2011329233A1 (en) | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| WO2015027214A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| PT3478679T (pt) * | 2016-07-01 | 2021-06-30 | Pfizer | Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas |
| GB201616839D0 (en) * | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
-
2018
- 2018-06-14 IL IL271290A patent/IL271290B2/en unknown
- 2018-06-14 SG SG11201913014YA patent/SG11201913014YA/en unknown
- 2018-06-14 US US16/625,202 patent/US11198692B2/en active Active
- 2018-06-14 PL PL18743584.7T patent/PL3642202T3/pl unknown
- 2018-06-14 BR BR112019026955-0A patent/BR112019026955A2/pt not_active Application Discontinuation
- 2018-06-14 AU AU2018287787A patent/AU2018287787A1/en not_active Abandoned
- 2018-06-14 MX MX2019015371A patent/MX2019015371A/es unknown
- 2018-06-14 CN CN201880049365.XA patent/CN110944998B/zh active Active
- 2018-06-14 KR KR1020207001865A patent/KR20200013783A/ko not_active Withdrawn
- 2018-06-14 FI FIEP18743584.7T patent/FI3642202T3/fi active
- 2018-06-14 CA CA3066986A patent/CA3066986A1/en active Pending
- 2018-06-14 WO PCT/IB2018/054390 patent/WO2018234953A1/en not_active Ceased
- 2018-06-14 ES ES18743584T patent/ES2937236T3/es active Active
- 2018-06-14 JP JP2019570547A patent/JP7263266B2/ja active Active
- 2018-06-14 EP EP18743584.7A patent/EP3642202B1/en active Active
- 2018-06-14 DK DK18743584.7T patent/DK3642202T3/da active
- 2018-06-14 HU HUE18743584A patent/HUE060914T2/hu unknown
- 2018-06-14 PT PT187435847T patent/PT3642202T/pt unknown
- 2018-06-19 TW TW107120944A patent/TWI680128B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524687A5 (https=) | ||
| JP2019519583A5 (https=) | ||
| US20080153811A1 (en) | Methods of Treating Cognitive Impairment and Dementia | |
| US20060258691A1 (en) | Methods and compositions for improving cognition | |
| ES2434467T3 (es) | Compuestos multicíclicos y métodos para su uso | |
| EP3371164B1 (en) | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| EP2863916B1 (en) | Substituted pyridine spleen tyrosine kinase (syk) inhibitors | |
| US8680116B2 (en) | Quinolinone PDE2 inhibitors | |
| JP2014501269A5 (https=) | ||
| US8658650B2 (en) | Substituted 1,1,3,1-tetraoxidobenzo[D][1,3,2]dithiazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| JP2018534326A5 (https=) | ||
| JP2019530695A5 (https=) | ||
| JP2021519269A5 (https=) | ||
| US20130065895A1 (en) | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| US10526323B2 (en) | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| JP2010524974A5 (https=) | ||
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| US20130210818A1 (en) | Novel Heterocyclic Compounds and Uses Thereof | |
| HRP20160049T1 (hr) | Supstituirani 4,5,6,7-tetrahidro-1h-pirazolo[4,3-c]piridini, njihova uporaba kao medikamenta, te farmaceutski pripravci koji ih sadrže | |
| US9850232B2 (en) | Heteroaromatic compounds and their use as dopamine D1 ligands | |
| JP2011519891A5 (https=) | ||
| FI3768669T3 (fi) | Piperatsiiniatsaspirojohdannaisia | |
| ES2389106T3 (es) | Compuestos de arilvinilazacicloalcano y métodos de preparación y usos de ellos |